This is the place for the latest information about our work here at Glaucoma Research Foundation and for current events in the world of eye health. All breakthroughs and insights are made possible through the dedication of researchers, and through the continued financial support and active involvement of the community.
This is the place for the latest information about our work here at Glaucoma Research Foundation and for current events in the world of eye health. All breakthroughs and insights are made possible through the dedication of researchers, and through the continued financial support and active involvement of the community.
Dr. Di Polo’s laboratory investigated the hypothesis that insulin can improve the survival and function of injured retinal ganglion cells and may be viable as an innovative glaucoma treatment.
In normal-tension glaucoma, the optic nerve gets damaged even though the eye pressure is within a normal range.
For the first time, thanks to improvements in how we measure the disease, researchers are studying and testing new therapeutic candidates for neuroprotection, neuroenhancement, and visual restoration.
Listen to the 2018 Weston Glaucoma Research Lecture delivered by Jeffrey Goldberg, MD, PhD, a principal investigator in the Catalyst for a Cure.
Although primary open-angle glaucoma is the most common type of glaucoma, there are many other types of eye disorders that fall under the spectrum of glaucoma.
What can be done to make reading easier for those with glaucoma? You can start by trying some things on your own.
New approaches to treating, managing, and even curing glaucoma are essential to patients and caregivers. Researchers are actively working to advance the field in several key areas.
Research outcomes from past Shaffer Grant recipients demonstrate the impact of this funding in catalyzing the growth, sustainability, and productivity of glaucoma research laboratories across the US.
August 29, 2018 — Alcon has issued a voluntary global recall of the CyPass microstent, effective immediately.
“I became interested in glaucoma because I liked the long-term aspect of it. It is through that long-term relationship that we can really get to know our patients and help them.” — Carla Siegfried, MD
A recent discovery from researchers at Massachusetts Eye and Ear and MIT is providing some new insights into what causes glaucoma.
Study indicates treatment using insulin may restore vision in glaucoma patients.
The Gleams Newsletter includes interviews, personal stories, and current information about glaucoma, new treatments, updates on research findings, and more. You can subscribe to the printed version of Gleams or the electronic version — both are free.
The Gleams Newsletter includes interviews, personal stories, and current information about glaucoma, new treatments, updates on research findings, and more. You can subscribe to the printed version of Gleams or the electronic version — both are free.
FOR EYECARE PROFESSIONALS
FOR EYECARE PROFESSIONALS
Glaucoma Research Foundation • 251 Post Street, Suite 600 • San Francisco, CA 94108 • 415-986-3162
Send us an email
We are a 501c3 tax-exempt national nonprofit. Our tax ID number is 94-2495035. Our EIN number is 94-2495035.
Copyright 2023 all rights reserved.
Print Subscription
We will mail Gleams anywhere in the United States and Canada, but we do not mail internationally. Please sign up for the email edition if you live outside of the US or Canada.
You can unsubscribe at any time. GRF will not share your personal information with any other organizations. Please see our Privacy Policy for further information.
E-mail Subscription
You can unsubscribe at any time. GRF will not share your personal information with any other organizations. Please see our Privacy Policy for further information.
